our findings in tgAPP mice, soluble A ␤ induced mitochondrial dysfunction in brain cells from tau transgenic mice. Conclusion: Our results indicate that mitochondrial dysfunction is exacerbated by the presence of soluble A ␤ species as a very early event during pathogenesis.
Introduction
Alzheimer's disease (AD) is the most frequent form of dementia among the elderly and is characterized by the neuropathological hallmarks of extracellular amyloid plaques and intracellular neurofibrillary tangles in the brain of AD patients. Amyloid plaques are composed of the ␤ -amyloid (A ␤ ) protein, derived from its precursor protein APP. Neurofibrillary lesions are formed from paired helical filaments composed of hyperphosphorylated tau protein, a microtubule-associated protein.
In recent years, attempts have been undertaken to identify the toxic species of A ␤ . The focus of attention has since shifted from fibrillar to oligomeric species of A ␤ as the large, insoluble A ␤ deposits which form the amyloid plaques in the limbic and association cortices of AD patients are in equilibrium with small, diffusible oligomers of the peptide that appear capable of interfering with hippocampal synaptic function and memory [1, 2] . In addi- tion, mitochondrial dysfunction and energy metabolism deficiencies are recognized as earliest events and correlated with impairments of cognitive abilities in AD [3] [4] [5] [6] . Nevertheless, the specific mechanisms leading to mitochondrial failure in AD are not well understood.
In order to elucidate the impact of A ␤ during the course of AD pathogenesis in vivo, we investigated the brains from APP transgenic animals before and at the age of onset of A ␤ plaques. Moreover, we previously provided evidence for a mitochondrial dysfunction in P301L tau transgenic mice, a strain modelling the tau pathology of AD [7] . In light of recent studies suggesting that soluble rather than fibrillar aggregated A ␤ might be the actual toxic species, the toxicity of different preparations of A ␤ is currently under investigation.
Methods
C57BL/6 mice aged 3 months bearing the human Swedish (KM595/596NL) and London (V717I) mutations in the 751-amino-acid form of the human amyloid precursor protein (tgAPP) under the control of a murine Thy-1 promoter, 3-month-old tgAPP/PS1 mutant mice [by crossing the tgAPP mice with HMGCoA reductase promoter-driven PS1 (M146L) transgenic mice], as well as age-matched nontransgenic wild-type (WT) littermates were used for the experiments [8, 9] . The tgAPP mice exhibit onset of A ␤ plaques at an age of 6 months, but the intracellular soluble A ␤ load is already detectable at 3 months of age [8, 10] , whereas in tgAPP/PS1 mice plaque onset starts at an age of 3 months [10, 11] . The tau transgenic mice express the human pathogenic mutation P301L of tau together with the longest human brain tau isoform (htau40) under the control of the neuronspecific murine Thy-1.2 promoter [12, 13] . P301L tau mice show tau hyperphosphorylation already at 3 months. Neurofibrillary tangle formation starts at 6 months of age. The mice were analyzed at 13-15 months of age. Cortical brain cell preparation, determination of mitochondrial membrane potential, and determination of ATP levels were obtained as previously described [7] . Soluble A ␤ 42 preparations were performed according to Gonghard and coworkers [14] .
Results and Conclusions
To further clarify the synergistic effects of aging and A ␤ pathology, we investigated mitochondrial function of cortical brain cells from transgenic mice (tgAPP and tgAPP/PS1) and WT mice. Of note, pronounced mitochondrial dysfunction in adult tgAPP mice, such as a drop in mitochondrial membrane potential ( fig. 1 a) and reduced ATP levels ( fig. 1 b) , already appeared at 3 months when elevated A ␤ levels but not yet A ␤ -containing plaques are present. In tgAPP/PS1 mice with a high A ␤ load exhibiting A ␤ plaques already at an age of 3 months, the strongest reductions in mitochondrial membrane potential and ATP levels were found ( fig. 1 a, b) . We conclude that A ␤ -depending mitochondrial dysfunction starts already at a very young age and accelerates substantially with increasing age and A ␤ load as well as accumulation.
In addition, we determined whether soluble A ␤ 42 would exert a more pronounced toxicity towards P301L tau transgenic mitochondria when compared to fibrillar A ␤ . Interestingly, our preliminary results indicate that oligomeric and fibrillar A ␤ 42 caused a similar decrease in mitochondrial membrane potential in cortical brain cells obtained from P301L tau transgenic mice (data not shown) suggesting that in developing treatment strategies, it may not be sufficient to target either oligomeric or fibrillar A ␤ species, but that the best approach is either to prevent formation of excess A ␤ at all or to assist in its rapid clearance. Rigorous scientific research has identified multiple interactive mechanisms that parallel and are likely causative for the development of AD. Evidence is provided that AD is triggered by soluble, neurotoxic assemblies of A ␤ , while the late-stage pathology landmarks of amyloid plaques and tangles potentiate toxicity by driving a vicious cycle of A ␤ generation and oxidation, mitochondrial damage, glucose hypometabolism, energy deficiency, each accelerating the other, since a deficiency in energy can, in turn, induce BACE1 activation leading to an increased production of A ␤ [15] .
Although the advancement in our understanding of the molecular mechanisms of AD has resulted in a dramatic enhancement of our ability to diagnose and treat the disorder, there is still a constant need for the identification of AD-specific abnormalities finally leading to neurodegeneration, which might open new ways for the development of more efficacious therapies. Based on this assumption, strategies involving efforts to protect cells at the mitochondrial level by stabilizing or restoring mitochondrial function or to interfere with the energy metabolism appear to be promising in preventing AD, besides strategies with regard to the treatment and/or removal of both A ␤ and tau pathology.
